Baxter International is a healthcare company that focuses on developing and providing a wide range of medical products and services to enhance patient care. The company specializes in creating innovative therapies and solutions for various health conditions, including renal and hospital care. With a strong emphasis on sustainability and improving patient outcomes, Baxter manufactures essential medical devices, pharmaceuticals, and biotechnology products that support the treatment of chronic diseases and acute medical conditions. Their commitment to research and development drives advancements in healthcare technology, helping to meet the needs of healthcare professionals and patients worldwide. Read More
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Baxter (BAX) To Contact Him Directly To Discuss Their Options
The Law Offices of Frank R. Cruz reminds investors of the upcoming December 15, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Baxter International, Inc. ("Baxter" or the "Company") (NYSE: BAX) securities between February 23, 2022 and October 29, 2025, inclusive (the “Class Period”).
LOS ANGELES, Dec. 11, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Baxter International Inc. (“Baxter” or “the Company”) (NYSE: BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, today announced data in collaboration with The University of Texas Medical Branch (UTMB Health) demonstrating the positive impact of smart infusion pump integration with hospital electronic medical records (EMRs) on patient safety, clinicians' bedside productivity and programming compliance. The analyses of more than one million infusions on Baxter’s Spectrum IQ large volume infusion pumps (LVP) at UTMB were presented at the American Society of Health-System Pharmacists (ASHP) 2025 Midyear Clinical Meeting, held Dec. 7 – Dec. 10, 2025.
Looking back on medical devices & supplies - diversified stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Baxter (NYSE:BAX) and its peers.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Baxter (BAX) To Contact Him Directly To Discuss Their Options
NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Baxter International, Inc. (“Baxter” or the “Company”) (NYSE: BAX) for violations of the federal securities laws on behalf of investors who purchased or acquired Baxter common stock between February 23, 2022 and July 30, 2025, inclusive (the “Class Period”).
NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
LOS ANGELES, Dec. 08, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Baxter International Inc. (“Baxter” or “the Company”) (NYSE: BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%.
But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Baxter International, Inc. (“Baxter” or the “Company”) (NYSE: BAX) for violations of the federal securities laws on behalf of investors who purchased or acquired Baxter securities between February 23, 2022 and July 30, 2025, inclusive (the “Class Period”).
NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of James Hardie Industries plc (NYSE:JHX) and Baxter International, Inc. (NYSE:BAX). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Baxter International Inc. (NYSE:BAX) (“Baxter” or the “Company”) today announced the consideration payable in connection with the previously announced cash tender offers for the 2026 Notes and 2027 Notes (each as defined below). The table below sets forth the Total Consideration (as defined below) for each series of Notes.
PHILADELPHIA, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Berger Montague advises shareholders of Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) about an investigation into Baxter’s Board of Directors for potential breaches of fiduciary duties to the Company and its shareholders in connection with Baxter’s marketing and sale of its Novum Large Volume Pump (“Novum LVP”).
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Baxter To Contact Him Directly To Discuss Their Options
LOS ANGELES, Dec. 04, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Baxter International Inc. (“Baxter” or “the Company”) (NYSE: BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Baxter International Inc. (NYSE:BAX) (“Baxter” or the “Company”) today announced the early tender results for the previously announced cash tender offers for the 2026 Notes and 2027 Notes (each as defined below). The tender offers are being made pursuant to the terms and conditions set forth in the offer to purchase, dated Nov. 19, 2025, as amended by the Company’s press release dated Nov. 19, 2025 (as it may be further amended or supplemented from time to time, the “Offer to Purchase”).
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains.
This unpredictability can shake out even the most experienced investors.
LOS ANGELES, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Baxter International Inc. (“Baxter” or “the Company”) (NYSE: BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) between February 23, 2022 and July 30, 2025, inclusive.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Baxter To Contact Him Directly To Discuss Their Options
